STOCK TITAN

[Form 4] MaxCyte, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

MaxCyte, Inc. (MXCT) – Form 4 insider filing dated 06/23/2025

Independent director Cynthia Collins reported an annual equity grant under the company’s non-employee director compensation program. The grant consists of:

  • 29,210 restricted stock units (RSUs) awarded on 06/18/2025 at no cost; each RSU converts into one common share upon vesting on 06/18/2026, assuming continuous board service.
  • 50,790 stock options with an exercise price of $2.11 per share, expiring 06/17/2035. Vesting details beyond the standard one-year cliff for RSUs were not disclosed in the filing.

Following the grant, Collins’ direct beneficial ownership increased to 80,889 common shares, strengthening alignment between the director and shareholders. Because the RSUs and options were granted by the company rather than purchased on the open market, the transaction incurs no immediate cash outlay by the insider and does not provide new pricing insight to investors.

No sales, dispositions, or other derivative transactions were reported, and the filing does not contain financial performance data or forward-looking statements. Overall, this is a routine governance disclosure reflecting the company’s ongoing equity-based compensation practice for directors.

MaxCyte, Inc. (MXCT) – Comunicazione interna Form 4 datata 23/06/2025

La direttrice indipendente Cynthia Collins ha comunicato una concessione annuale di azioni nell’ambito del programma di compensazione per direttori non dipendenti della società. La concessione comprende:

  • 29.210 unità azionarie vincolate (RSU) assegnate il 18/06/2025 senza alcun costo; ogni RSU si trasformerà in un’azione ordinaria al momento della maturazione il 18/06/2026, a condizione che la Collins continui a far parte del consiglio.
  • 50.790 opzioni su azioni con un prezzo di esercizio di $2,11 per azione, con scadenza il 17/06/2035. I dettagli sul periodo di maturazione oltre il consueto cliff di un anno per le RSU non sono stati resi noti nel documento.

In seguito alla concessione, la posizione diretta di proprietà di Collins è aumentata a 80.889 azioni ordinarie, rafforzando l’allineamento tra la direttrice e gli azionisti. Poiché le RSU e le opzioni sono state assegnate dalla società e non acquistate sul mercato, l’operazione non comporta un esborso immediato di denaro da parte dell’insider e non fornisce nuovi elementi di prezzo agli investitori.

Non sono state segnalate vendite, cessioni o altre transazioni derivate, e il documento non contiene dati finanziari o dichiarazioni previsionali. Nel complesso, si tratta di una comunicazione ordinaria di governance che riflette la prassi continua della società di compensazione basata su azioni per i membri del consiglio.

MaxCyte, Inc. (MXCT) – Presentación interna Formulario 4 fechada 23/06/2025

La directora independiente Cynthia Collins informó una concesión anual de acciones bajo el programa de compensación para directores no empleados de la empresa. La concesión consiste en:

  • 29,210 unidades de acciones restringidas (RSU) otorgadas el 18/06/2025 sin costo; cada RSU se convierte en una acción común al consolidarse el 18/06/2026, suponiendo que continúe en el consejo.
  • 50,790 opciones sobre acciones con un precio de ejercicio de $2.11 por acción, que expiran el 17/06/2035. No se revelaron detalles sobre el período de consolidación más allá del período inicial de un año para las RSU.

Tras la concesión, la propiedad directa de Collins aumentó a 80,889 acciones comunes, reforzando la alineación entre la directora y los accionistas. Dado que las RSU y las opciones fueron otorgadas por la empresa y no compradas en el mercado abierto, la transacción no implica un desembolso inmediato de efectivo por parte del insider ni aporta nueva información de precios para los inversores.

No se reportaron ventas, disposiciones u otras transacciones derivadas, y la presentación no contiene datos financieros ni declaraciones prospectivas. En general, se trata de una divulgación rutinaria de gobernanza que refleja la práctica continua de la empresa de compensación basada en acciones para los directores.

MaxCyte, Inc. (MXCT) – 2025년 6월 23일자 내부자 신고서(Form 4)

독립 이사 Cynthia Collins가 회사의 비임원 이사회 보상 프로그램에 따른 연간 주식 부여를 보고했습니다. 부여 내용은 다음과 같습니다:

  • 29,210 제한 주식 단위(RSUs)가 2025년 6월 18일 무상으로 부여되었으며, 각 RSU는 2026년 6월 18일에 계속 이사회에 재직하는 조건으로 1주 보통주로 전환됩니다.
  • 50,790 주식 매수선택권으로 행사 가격은 주당 $2.11이며, 만료일은 2035년 6월 17일입니다. RSU에 대한 1년 대기 기간 외의 추가 권리 취득 조건은 공개되지 않았습니다.

이번 부여로 Collins의 직접 보유 주식 수80,889주로 증가하여 이사와 주주 간 이해관계가 더욱 강화되었습니다. RSU와 옵션은 회사에서 부여한 것이며 시장에서 매입한 것이 아니므로, 내부자는 즉각적인 현금 지출이 없고 투자자에게 새로운 가격 정보도 제공하지 않습니다.

판매, 처분 또는 기타 파생 거래는 보고되지 않았으며, 신고서에는 재무 성과 데이터나 미래 전망 진술도 포함되어 있지 않습니다. 전반적으로 이번 공시는 이사에 대한 회사의 지속적인 주식 기반 보상 관행을 반영하는 일상적인 거버넌스 공개입니다.

MaxCyte, Inc. (MXCT) – Déclaration d’initié Formulaire 4 datée du 23/06/2025

La directrice indépendante Cynthia Collins a signalé une attribution annuelle d’actions dans le cadre du programme de rémunération des administrateurs non salariés de la société. L’attribution comprend :

  • 29 210 unités d’actions restreintes (RSU) attribuées le 18/06/2025 sans frais ; chaque RSU se convertira en une action ordinaire à la date d’acquisition des droits le 18/06/2026, sous réserve d’un service continu au conseil d’administration.
  • 50 790 options d’achat d’actions avec un prix d’exercice de 2,11 $ par action, expirant le 17/06/2035. Les détails de l’acquisition des droits au-delà de la période d’un an pour les RSU n’ont pas été divulgués dans le document.

À la suite de cette attribution, la possession directe de Collins a augmenté à 80 889 actions ordinaires, renforçant l’alignement entre la directrice et les actionnaires. Comme les RSU et options ont été attribuées par la société et non achetées sur le marché libre, cette opération n’entraîne aucune sortie de trésorerie immédiate pour l’initié et n’offre pas de nouvelle indication sur les prix aux investisseurs.

Aucune vente, cession ou autre transaction dérivée n’a été signalée, et le document ne contient pas de données financières ni de déclarations prospectives. Globalement, il s’agit d’une divulgation de gouvernance de routine reflétant la pratique continue de la société en matière de rémunération en actions pour les administrateurs.

MaxCyte, Inc. (MXCT) – Insider-Meldung Form 4 vom 23.06.2025

Die unabhängige Direktorin Cynthia Collins meldete eine jährliche Aktienzuteilung im Rahmen des Vergütungsprogramms für nicht-angestellte Direktoren des Unternehmens. Die Zuteilung umfasst:

  • 29.210 Restricted Stock Units (RSUs), die am 18.06.2025 kostenfrei gewährt wurden; jede RSU wandelt sich bei Vesting am 18.06.2026 in eine Stammaktie um, vorausgesetzt, die Board-Mitgliedschaft wird fortgesetzt.
  • 50.790 Aktienoptionen mit einem Ausübungspreis von 2,11 $ pro Aktie, Laufzeit bis 17.06.2035. Details zum Vesting über die übliche einjährige Cliff-Periode für RSUs hinaus wurden nicht offengelegt.

Nach der Zuteilung erhöhte sich Collins’ direkter Besitz auf 80.889 Stammaktien, was die Ausrichtung zwischen Direktorin und Aktionären stärkt. Da die RSUs und Optionen vom Unternehmen gewährt wurden und nicht am freien Markt gekauft wurden, entstehen dem Insider keine sofortigen Ausgaben, und es liefert keine neuen Preisinformationen für Investoren.

Es wurden keine Verkäufe, Veräußerungen oder sonstige Derivatgeschäfte gemeldet, und die Meldung enthält keine Finanzkennzahlen oder zukunftsgerichteten Aussagen. Insgesamt handelt es sich um eine routinemäßige Governance-Offenlegung, die die fortlaufende aktienbasierte Vergütungspraxis für Direktoren des Unternehmens widerspiegelt.

Positive
  • Director’s beneficial ownership rises to 80,889 shares, marginally increasing insider alignment with shareholders.
  • No shares were sold, indicating continued confidence and commitment by the director.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; improves alignment, minimal market impact.

The filing shows MaxCyte issued standard annual equity to director Cynthia Collins—29,210 RSUs and 50,790 options at $2.11. Such grants are customary for U.S. small-cap biotech boards and create modest additional dilution but enhance director–shareholder alignment. Because the RSUs vest in one year and the options are out-of-the-money unless MXCT trades above $2.11, immediate valuation impact is negligible. No open-market buying or selling occurred, so signal value is limited. Investors may view continued board retention positively, yet the transaction does not materially change ownership structure or capital allocation.

MaxCyte, Inc. (MXCT) – Comunicazione interna Form 4 datata 23/06/2025

La direttrice indipendente Cynthia Collins ha comunicato una concessione annuale di azioni nell’ambito del programma di compensazione per direttori non dipendenti della società. La concessione comprende:

  • 29.210 unità azionarie vincolate (RSU) assegnate il 18/06/2025 senza alcun costo; ogni RSU si trasformerà in un’azione ordinaria al momento della maturazione il 18/06/2026, a condizione che la Collins continui a far parte del consiglio.
  • 50.790 opzioni su azioni con un prezzo di esercizio di $2,11 per azione, con scadenza il 17/06/2035. I dettagli sul periodo di maturazione oltre il consueto cliff di un anno per le RSU non sono stati resi noti nel documento.

In seguito alla concessione, la posizione diretta di proprietà di Collins è aumentata a 80.889 azioni ordinarie, rafforzando l’allineamento tra la direttrice e gli azionisti. Poiché le RSU e le opzioni sono state assegnate dalla società e non acquistate sul mercato, l’operazione non comporta un esborso immediato di denaro da parte dell’insider e non fornisce nuovi elementi di prezzo agli investitori.

Non sono state segnalate vendite, cessioni o altre transazioni derivate, e il documento non contiene dati finanziari o dichiarazioni previsionali. Nel complesso, si tratta di una comunicazione ordinaria di governance che riflette la prassi continua della società di compensazione basata su azioni per i membri del consiglio.

MaxCyte, Inc. (MXCT) – Presentación interna Formulario 4 fechada 23/06/2025

La directora independiente Cynthia Collins informó una concesión anual de acciones bajo el programa de compensación para directores no empleados de la empresa. La concesión consiste en:

  • 29,210 unidades de acciones restringidas (RSU) otorgadas el 18/06/2025 sin costo; cada RSU se convierte en una acción común al consolidarse el 18/06/2026, suponiendo que continúe en el consejo.
  • 50,790 opciones sobre acciones con un precio de ejercicio de $2.11 por acción, que expiran el 17/06/2035. No se revelaron detalles sobre el período de consolidación más allá del período inicial de un año para las RSU.

Tras la concesión, la propiedad directa de Collins aumentó a 80,889 acciones comunes, reforzando la alineación entre la directora y los accionistas. Dado que las RSU y las opciones fueron otorgadas por la empresa y no compradas en el mercado abierto, la transacción no implica un desembolso inmediato de efectivo por parte del insider ni aporta nueva información de precios para los inversores.

No se reportaron ventas, disposiciones u otras transacciones derivadas, y la presentación no contiene datos financieros ni declaraciones prospectivas. En general, se trata de una divulgación rutinaria de gobernanza que refleja la práctica continua de la empresa de compensación basada en acciones para los directores.

MaxCyte, Inc. (MXCT) – 2025년 6월 23일자 내부자 신고서(Form 4)

독립 이사 Cynthia Collins가 회사의 비임원 이사회 보상 프로그램에 따른 연간 주식 부여를 보고했습니다. 부여 내용은 다음과 같습니다:

  • 29,210 제한 주식 단위(RSUs)가 2025년 6월 18일 무상으로 부여되었으며, 각 RSU는 2026년 6월 18일에 계속 이사회에 재직하는 조건으로 1주 보통주로 전환됩니다.
  • 50,790 주식 매수선택권으로 행사 가격은 주당 $2.11이며, 만료일은 2035년 6월 17일입니다. RSU에 대한 1년 대기 기간 외의 추가 권리 취득 조건은 공개되지 않았습니다.

이번 부여로 Collins의 직접 보유 주식 수80,889주로 증가하여 이사와 주주 간 이해관계가 더욱 강화되었습니다. RSU와 옵션은 회사에서 부여한 것이며 시장에서 매입한 것이 아니므로, 내부자는 즉각적인 현금 지출이 없고 투자자에게 새로운 가격 정보도 제공하지 않습니다.

판매, 처분 또는 기타 파생 거래는 보고되지 않았으며, 신고서에는 재무 성과 데이터나 미래 전망 진술도 포함되어 있지 않습니다. 전반적으로 이번 공시는 이사에 대한 회사의 지속적인 주식 기반 보상 관행을 반영하는 일상적인 거버넌스 공개입니다.

MaxCyte, Inc. (MXCT) – Déclaration d’initié Formulaire 4 datée du 23/06/2025

La directrice indépendante Cynthia Collins a signalé une attribution annuelle d’actions dans le cadre du programme de rémunération des administrateurs non salariés de la société. L’attribution comprend :

  • 29 210 unités d’actions restreintes (RSU) attribuées le 18/06/2025 sans frais ; chaque RSU se convertira en une action ordinaire à la date d’acquisition des droits le 18/06/2026, sous réserve d’un service continu au conseil d’administration.
  • 50 790 options d’achat d’actions avec un prix d’exercice de 2,11 $ par action, expirant le 17/06/2035. Les détails de l’acquisition des droits au-delà de la période d’un an pour les RSU n’ont pas été divulgués dans le document.

À la suite de cette attribution, la possession directe de Collins a augmenté à 80 889 actions ordinaires, renforçant l’alignement entre la directrice et les actionnaires. Comme les RSU et options ont été attribuées par la société et non achetées sur le marché libre, cette opération n’entraîne aucune sortie de trésorerie immédiate pour l’initié et n’offre pas de nouvelle indication sur les prix aux investisseurs.

Aucune vente, cession ou autre transaction dérivée n’a été signalée, et le document ne contient pas de données financières ni de déclarations prospectives. Globalement, il s’agit d’une divulgation de gouvernance de routine reflétant la pratique continue de la société en matière de rémunération en actions pour les administrateurs.

MaxCyte, Inc. (MXCT) – Insider-Meldung Form 4 vom 23.06.2025

Die unabhängige Direktorin Cynthia Collins meldete eine jährliche Aktienzuteilung im Rahmen des Vergütungsprogramms für nicht-angestellte Direktoren des Unternehmens. Die Zuteilung umfasst:

  • 29.210 Restricted Stock Units (RSUs), die am 18.06.2025 kostenfrei gewährt wurden; jede RSU wandelt sich bei Vesting am 18.06.2026 in eine Stammaktie um, vorausgesetzt, die Board-Mitgliedschaft wird fortgesetzt.
  • 50.790 Aktienoptionen mit einem Ausübungspreis von 2,11 $ pro Aktie, Laufzeit bis 17.06.2035. Details zum Vesting über die übliche einjährige Cliff-Periode für RSUs hinaus wurden nicht offengelegt.

Nach der Zuteilung erhöhte sich Collins’ direkter Besitz auf 80.889 Stammaktien, was die Ausrichtung zwischen Direktorin und Aktionären stärkt. Da die RSUs und Optionen vom Unternehmen gewährt wurden und nicht am freien Markt gekauft wurden, entstehen dem Insider keine sofortigen Ausgaben, und es liefert keine neuen Preisinformationen für Investoren.

Es wurden keine Verkäufe, Veräußerungen oder sonstige Derivatgeschäfte gemeldet, und die Meldung enthält keine Finanzkennzahlen oder zukunftsgerichteten Aussagen. Insgesamt handelt es sich um eine routinemäßige Governance-Offenlegung, die die fortlaufende aktienbasierte Vergütungspraxis für Direktoren des Unternehmens widerspiegelt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Cynthia

(Last) (First) (Middle)
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400

(Street)
ROCKVILLE MD 20850

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 29,210(1)(2) A $0 80,889 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $2.11 06/18/2025 A 50,790 (2) 06/17/2035 Common Stock 50,790 $0 50,790 D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.
/s/ David Sandoval, Attorney-in-Fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MaxCyte (MXCT) disclose in the latest Form 4?

MXCT reported a routine annual grant of 29,210 RSUs and 50,790 stock options to director Cynthia Collins.

How many shares does Cynthia Collins now own in MXCT?

After the grant, Collins directly beneficially owns 80,889 common shares.

What is the exercise price and expiration of the new MXCT options?

The options have a $2.11 exercise price and expire on 06/17/2035.

When will the 29,210 RSUs granted to Cynthia Collins vest?

The RSUs vest on 06/18/2026, subject to continuous board service.

Did the director purchase any MXCT shares on the open market?

No. The filing only reflects company-granted RSUs and options; no open-market purchases were reported.
Maxcyte

NASDAQ:MXCT

MXCT Rankings

MXCT Latest News

MXCT Latest SEC Filings

MXCT Stock Data

188.69M
99.61M
1.77%
75.41%
3.08%
Medical Devices
Services-commercial Physical & Biological Research
Link
United States
ROCKVILLE